Amorfix in-licenses second novel technology to strengthen ALS therapeutic program

By Lisa Kerner

Erie, Pa., April 4 - Amorfix Life Sciences Ltd. said it has obtained the exclusive worldwide rights to additional novel targets on Superoxide Dismutase-1 (SOD1), a protein known to misfold and aggregate in the neurological disease Amyotrophic Lateral Sclerosis (ALS).

These new SOD1 targets broaden Amorfix's intellectual property estate on SOD1 and enhance its existing diagnostic and therapeutic strategies for the treatment of ALS, according to a company news release.

The company said it also obtained an option to acquire the intellectual property and know-how surrounding the licensed technology.

Amorfix chief scientific officer Neil Cashman co-discovered the novel SOD1 targets and has since assigned his portion of the technology rights to the company. Amorfix has licensed the remaining rights from University Health Network (UHN), committing a minimum of $260,000 on development of the technology at UHN.

Toronto-based Amorfix is an emerging theranostics company focused on the diagnosis and treatment of neurodegenerative diseases where aggregated misfolded proteins are prevalent.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.